| |
STEMI
|
NSTE-ACS
|
|---|
|
Diabetes/possible diabetes (N = 14,650)
|
No diabetes (N = 25,143)
|
p value
|
Diabetes/possible diabetes (N = 9230)
|
No diabetes (N = 14,427)
|
p value
|
|---|
|
DAPT, % (n/N)
|
95.4 (13,911/14,577)
|
95.5 (23,915/25,037)
|
0.686
|
89.4 (8130/9098)
|
90.0 (12,827/14,250)
|
0.108
|
|
Aspirin, % (n/N)
|
96.3 (14,032/14,579)
|
96.5 (24,163/25,038)
|
0.184
|
93.1 (8469/9100)
|
93.6 (13,343/14,253)
|
0.099
|
|
P2Y12 inhibitors, % (n/N)
|
96.9 (14,194/14,643)
|
96.7 (24,295/25,135)
|
0.134
|
92.7 (8534/9211)
|
92.9 (13,394/14,411)
|
0.395
|
|
GPIIb/IIIa, % (n/N)
|
39.8 (5816/14,625)
|
38.4 (9651/25,112)
|
0.008
|
17.5 (1612/9196)
|
17.3 (2494/14,406)
|
0.668
|
|
Anticoagulant, % (n/N)
|
79.4 (11,632/14,643)
|
79.2 (19,912/25,135)
|
0.606
|
68.1 (6273/9211)
|
67.1 (9668/14,411)
|
0.104
|
|
UFH
|
5.3 (768/14,623)
|
4.5 (1121/25,097)
|
< 0.001
|
2.0 (185/9171)
|
1.9 (271/14,379)
|
0.472
|
|
LMWH
|
73.0 (10,676/14,623)
|
73.7 (18,490/25,097)
|
0.147
|
62.8 (5760/9171)
|
62.4 (8969/14,379)
|
0.505
|
|
Fondaparinux sodium
|
1.3 (186/14,623)
|
1.0 (262/25,097)
|
0.038
|
2.2 (201/9171)
|
1.6 (232/14,379)
|
0.001
|
|
Other anticoagulants
|
1.9 (280/14,623)
|
2.0 (512/25,097)
|
0.389
|
2.0 (185/9171)
|
2.0 (280/14,379)
|
0.707
|
|
Statins, % (n/N)
|
94.1(37,382/39,735)
|
94.0 (13,748/14,628)
|
0.544
|
92.9 (8562/9212)
|
93.4 (13,459/14,408)
|
0.161
|
|
Beta-blockers, % (n/N)
|
64.3 (2917/4536)
|
62.5 (4998/7997)
|
0.044
|
67.6 (2046/3028)
|
66.4 (3431/5164)
|
0.295
|
|
ACEI/ARB, % (n/N)
|
49.8 (6687/13,427)
|
48.4 (11,151/23,030)
|
0.011
|
54.0 (4643/8606)
|
48.8 (6535/13,396)
|
< 0.001
|
|
PCI, % (n/N)
|
77.1 (11,289/14,650)
|
77.5 (19,484/25,143)
|
< 0.001
|
58.2 (5367/9230)
|
61.1 (8810/14,427)
|
0.006
|
|
Time of PCIa, % (n/N) (h)
| | |
< 0.001
| | |
0.006
|
|
< 2
|
55.2 (8574/15,526)
|
57.4 (5220/9100)
| |
10.0 (734/7341)
|
8.9 (388/4383)
| |
|
2–11.9
|
10.2 (1577/15,526)
|
11.5 (1046/9100)
| |
10.0 (731/7341)
|
10.8 (474/4383)
| |
|
12–23.9
|
3.2 (493/15,526)
|
3.4 (313/9100)
| |
7.8 (572/7341)
|
7.2 (314/4383)
| |
|
24–71.9
|
9.8 (1524/15,526)
|
8.9 (809/9100)
| |
31.2 (2293/7341)
|
29.5 (1294/4383)
| |
|
≥ 72
|
21.6 (3358/15,526)
|
18.8 (1712/9100)
| |
41.0 (3011/7341)
|
43.7 (1913/4383)
| |
|
Type of stentsb, % (n/N)
| | |
0.010
| | |
0.088
|
|
Drug eluting stent
|
98.1 (9827/10,017)
|
98.1 (16,825/17,145)
| |
96.9 (4317/4456)
|
96.7 (6997/7235)
| |
|
Bare metal stent
|
1.0 (101/10,017)
|
1.2 (213/17,145)
| |
1.8 (82/4456)
|
1.6 (113/7235)
| |
|
Other
|
0.9 (89/10,017)
|
0.6 (107/17,145)
| |
1.3 (57/4456)
|
1.7 (125/7235)
| |
|
CABG, % (n/N)
|
0.5 (46/10,121)
|
0.5 (94/17,328)
|
0.324
|
0.7 (33/4670)
|
0.7 (51/7583)
|
0.824
|
|
Length of stay, median (IQR), day
|
10.0 (7.0–13.0)
|
10.0 (7.0–13.0)
|
< 0.001
|
10.0 (7.0–13.0)
|
9.0 (7.0–12.0)
|
< 0.001
|
- STEMI ST-segment elevation myocardial infarction, NSTE-ACS non-ST-segment elevation acute coronary syndrome, DAPT dual antiplatelet therapy, UFH unfractionated heparin, LMWH low molecular weight heparin, PCI percutaneous coronary intervention, CABG coronary artery bypass grafting
- The usage rate of drugs was calculated in patients without drug contraindications
- a Time of PCI, time from admission to PCI, and detailed data of time of PCI were not available for 8600 patients with PCI
- b Type of stents and type of PCI were not available for 849 patients with stent implantation
